These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 10802863)

  • 41. Oral immunization against Helicobacter pylori--a future concept.
    Michetti P
    J Gastroenterol; 1998; 33 Suppl 10():66-8. PubMed ID: 9840022
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunoinformatics Approach to Design a Novel Epitope-Based Oral Vaccine Against
    Urrutia-Baca VH; Gomez-Flores R; De La Garza-Ramos MA; Tamez-Guerra P; Lucio-Sauceda DG; Rodríguez-Padilla MC
    J Comput Biol; 2019 Oct; 26(10):1177-1190. PubMed ID: 31120321
    [No Abstract]   [Full Text] [Related]  

  • 43. Helivax Antex Biologics.
    Giudice GD
    Curr Opin Investig Drugs; 2001 Jul; 2(7):896-9. PubMed ID: 11757787
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preclinical immunogenicity and protective efficacy of an oral Helicobacter pylori inactivated whole cell vaccine and multiple mutant cholera toxin: A novel and non-toxic mucosal adjuvant.
    Holmgren J; Nordqvist S; Blomquist M; Jeverstam F; Lebens M; Raghavan S
    Vaccine; 2018 Oct; 36(41):6223-6230. PubMed ID: 30119923
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vaccine development against infection with Helicobacter pylori.
    Kleanthous H; Lee CK; Monath TP
    Br Med Bull; 1998; 54(1):229-41. PubMed ID: 9604446
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mucosal vaccination increases local chemokine production attracting immune cells to the stomach mucosa of Helicobacter pylori infected mice.
    Flach CF; Mozer M; Sundquist M; Holmgren J; Raghavan S
    Vaccine; 2012 Feb; 30(9):1636-43. PubMed ID: 22230589
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunization of rhesus monkeys with a mucosal prime, parenteral boost strategy protects against infection with Helicobacter pylori.
    Lee CK; Soike K; Giannasca P; Hill J; Weltzin R; Kleanthous H; Blanchard J; Monath TP
    Vaccine; 1999 Aug; 17(23-24):3072-82. PubMed ID: 10462242
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Therapeutic oral vaccination induces mucosal immune response sufficient to eliminate long-term Helicobacter pylori infection.
    Ikewaki J; Nishizono A; Goto T; Fujioka T; Mifune K
    Microbiol Immunol; 2000; 44(1):29-39. PubMed ID: 10711597
    [TBL] [Abstract][Full Text] [Related]  

  • 49. How far are we from vaccination against Helicobacter pylori infection?
    Stubljar D; Jukic T; Ihan A
    Expert Rev Vaccines; 2018 Oct; 17(10):935-945. PubMed ID: 30238819
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization.
    Akhiani AA; Stensson A; Schön K; Lycke N
    Scand J Immunol; 2006 Feb; 63(2):97-105. PubMed ID: 16476008
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gastric Subserous Vaccination With
    Liu W; Zeng Z; Luo S; Hu C; Xu N; Huang A; Zheng L; Sundberg EJ; Xi T; Xing Y
    Front Immunol; 2019; 10():1115. PubMed ID: 31156652
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunology and vaccines and nanovaccines for Helicobacter pylori infection.
    Milani M; Sharifi Y; Rahmati-Yamchi M; Somi MH; Akbarzadeh A
    Expert Rev Vaccines; 2015 Jun; 14(6):833-40. PubMed ID: 25645086
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Protection against Helicobacter pylori infection in mongolian gerbil by intragastric or intramuscular administration of H. pylori multicomponent vaccine.
    Wu C; Shi Y; Guo H; Zou WY; Guo G; Xie QH; Mao XH; Tong WD; Zou QM
    Helicobacter; 2008 Jun; 13(3):191-9. PubMed ID: 18466394
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of ISCOMATRIX and ISCOM vaccines for immunisation against Helicobacter pylori.
    Skene CD; Doidge C; Sutton P
    Vaccine; 2008 Jul; 26(31):3880-4. PubMed ID: 18547687
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study.
    Malfertheiner P; Schultze V; Rosenkranz B; Kaufmann SH; Ulrichs T; Novicki D; Norelli F; Contorni M; Peppoloni S; Berti D; Tornese D; Ganju J; Palla E; Rappuoli R; Scharschmidt BF; Del Giudice G
    Gastroenterology; 2008 Sep; 135(3):787-95. PubMed ID: 18619971
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alkyl hydroperoxide reductase: a candidate Helicobacter pylori vaccine.
    O'Riordan AA; Morales VA; Mulligan L; Faheem N; Windle HJ; Kelleher DP
    Vaccine; 2012 Jun; 30(26):3876-84. PubMed ID: 22512976
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The current status of Helicobacter pylori vaccines: a review.
    Kabir S
    Helicobacter; 2007 Apr; 12(2):89-102. PubMed ID: 17309745
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunity, inflammation, and vaccines for Helicobacter pylori.
    D'Elios MM; Czinn SJ
    Helicobacter; 2014 Sep; 19 Suppl 1():19-26. PubMed ID: 25167941
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dendritic cells prevent rather than promote immunity conferred by a helicobacter vaccine using a mycobacterial adjuvant.
    Hitzler I; Oertli M; Becher B; Agger EM; Müller A
    Gastroenterology; 2011 Jul; 141(1):186-96, 196.e1. PubMed ID: 21569773
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunological features and efficacy of the reconstructed epitope vaccine CtUBE against Helicobacter pylori infection in BALB/c mice model.
    Guo L; Liu K; Zhao W; Li X; Li T; Tang F; Zhang R; Wu W; Xi T
    Appl Microbiol Biotechnol; 2013 Mar; 97(6):2367-78. PubMed ID: 23064457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.